For the year ending 2025-12-31, CLRB had -$10,092,574 decrease in cash & cash equivalents over the period. -$23,124,097 in free cash flow.
| Cash Flow | 2025-12-31 |
|---|---|
| Net loss | -21,791,037 |
| Depreciation and amortization | 213,597 |
| Stock-based compensation | 2,263,704 |
| Change in fair value of warrants | -753,707 |
| Change in operating lease right-of-use asset | 76,202 |
| Prepaid expenses and other assets | -119,233 |
| Accounts payable and accrued liabilities | -3,161,792 |
| Lease liability | -84,417 |
| Cash used in operating activities | -23,118,217 |
| Purchases of property, plant & equipment | 5,880 |
| Cash used in investing activities | -5,880 |
| Proceeds from exercise of warrants and new warrants, net of issuance costs | 7,243,143 |
| Proceeds from issuance of common stock, pre-funded warrants and common warrants, net of issuance costs | 5,788,380 |
| Cash provided by financing activities | 13,031,523 |
| Increase (decrease) in cash and cash equivalents | -10,092,574 |
| Cash and cash equivalents at beginning of period | 23,288,607 |
| Cash and cash equivalents at end of period | 13,196,033 |
Cellectar Biosciences, Inc. (CLRB)
Cellectar Biosciences, Inc. (CLRB)